Jupiter Life Line Hospitals Limited — Q4 FY25 earnings call

Call held 12 May 2025

Management summary

Jupiter Life Line Hospitals delivered strong FY25 results with significant revenue and EBITDA growth, driven by healthy ARPOB and occupancy rates. The company is actively pursuing its expansion strategy, with new bed additions in Indore and progress on greenfield projects in Dombivli and Pune. Strategic debt raising has bolstered liquidity, positioning the company for continued growth, though Q4 PAT saw a slight dip due to higher depreciation.

Highlights

  • FY25 Income grew 17.5% YoY to ₹1,261.5 crores.

  • FY25 EBITDA increased 22.5% YoY to ₹296.6 crores, with EBITDA margin at 23.5%.

  • FY25 ARPOB rose 10.4% YoY to ₹60,600.

  • The company's initial target of establishing 2,500 beds in Western India is now within sight.

  • A robust cash position of ₹600 crores, including ₹325 crores from new debt and ₹275 crores from existing reserves, provides strong liquidity for expansion.

Concerns

  • Q4 FY25 PAT declined 0.9% YoY to ₹44.9 crores, primarily due to increased depreciation.

  • Indore's Q4 occupancy was lower at 42.1%, attributed to the dilution effect from commissioning 78 new beds.

Key financials

2 periods

Q4 FY25

  • ARPOB
    ₹65,453
    YoY +10%

FY25

  • Income
    ₹1,261.5 Cr
    YoY +17.5%
  • EBITDA
    ₹296.6 Cr
    YoY +22.5%
  • EBITDA Margin
    23.5%
  • PAT
    ₹193.5 Cr
  • ARPOB
    ₹60,600
    YoY +10.4%
  • Average Occupancy
    65.3%

What they filed

Q1 FY27: revenue up 16.4%, net profit down 13.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue335 333 337 353 394 +18%365 +10%388 +15%411 +16%
EBITDA78 76 80 78 92 +18%83 +9%89 +11%79 +1%
Net profit52 52 45 44 57 +10%42 −19%50 +11%38 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentOccupancy (FY25)Occupancy (Q4 FY25)
Thane Hospital72.1%71.1%
Pune Hospital65.5%61.1%
Indore Hospital54.9%42.1%

Capital allocation

high confidence
  • Capex Capex disclosed Existing cash reserves and internal accruals, supplemented by additional debt.
    • Pune greenfield hospital (500 beds) ₹500 Cr
    • Indore expansion (78 new beds, 11-bed ICU)
    • Thane facility upgrades (2 new OTs, 2nd MRI, 2nd cardiac cath lab, expanded Daycare/chemo suites, new OPD cluster, engineering infrastructure overhaul)
    Over the next 4, 5 years, as these hospitals become operational, we are confident that the operating cash flows generated should be sufficient to fund this capex and their ongoing operations. However, while 6 hospitals represented our initial target, they are certainly not the final destination. We are exploring some opportunities in addition to the above 6, which could be greenfield or in the form of an acquisition. With this in mind, we have raised additional debt to fund these new projects.
  • Debt Debt disclosed Cost 1%
    • New borrowing Debt raised within Indore subsidiary (JHPPL) to repay intercompany loan. ₹250 Cr
    • New borrowing Sanctioned loan for capex for the listed entity, with INR 75 crores drawn. ₹350 Cr
    Let me begin with our subsidiary, JHPPL, which operates our Indore hospital. Following our listing and primary equity raise, we had extended a loan to our Indore subsidiary to facilitate the repayment of their bank obligations and also to fund some of their capex initiatives. We have now raised an INR250 crores debt within our Indore subsidiary to repay our intercompany loan. ... Turning to the listed entity. We have secured a sanction of INR350 crores loan, which is earmarked for capex. Of this sanctioned amount, we have drawn INR75 crores. ... The cost of carrying this loan is expected to be less than 1%.
  • Liquidity Cash ₹600 Cr · Undrawn ₹275 Cr Cash position includes INR 325 crores from new debt and INR 275 crores from existing cash reserves. The remaining INR 275 crores from the sanctioned debt facility is available for capex plans.
    As you see on our balance sheet today, our cash position stands at about INR600 crores, comprising of INR325 crores from the new debt and INR275 crores from our existing cash reserves. In this financial year, we have also undertaken several significant brownfield capex initiatives. ... We have the option to utilize the remaining INR275 crores from this debt facility to fund our capex plans, which could be anywhere, Dombivli, Pune or something else.

Guidance & targets

Capacity

  • Total beds in Western India Capacity · within sight · High confidence 2,500 beds
    So we have consistently communicated that our post-listing initial objective was to establish 2,500 beds and expand our networks from 3 to 6 hospitals. We believe that we could achieve this milestone by leveraging our existing cash reserves and internal accruals. I'm pleased to report that this first target of 2,500 beds in the Western India region is now within sight.

    — Ankit Thakker

  • Pune Hospital bed capacity Capacity · High confidence 500 beds
    So the new Pune hospital is supposed to be 500 beds in size.

    — Ankit Thakker

ARPOB Growth

  • ARPOB growth for Thane and Pune ARPOB Growth · next year · High confidence inflation-linked
    No, I don't expect 10% to continue. As I was saying that the projection for ARPOB growth should be inflation-linked. Thane and Pune, both are matured hospitals. So besides inflation, there is no other lever for ARPOB growth.

    — Ankit Thakker

  • ARPOB growth for Indore ARPOB Growth · maybe one more year · Medium confidence slightly higher than inflation
    Indore may be slightly higher than inflation because for maybe one more year, it has a second lever that is of case mix optimization that is more tertiary work. So Indore may have an extra lever for maybe another year or so.

    — Ankit Thakker

Volume Growth

  • Volume growth for Thane Volume Growth · next year · High confidence stable
    The volume in Thane should be stable. In Pune and Indore, we could expect some growth in volumes.

    — Ankit Thakker

  • Volume growth for Pune and Indore Volume Growth · next year · Medium confidence some growth

    — Ankit Thakker

Commissioning

  • Dombivli Hospital commissioning Commissioning · Q1 of FY '27 · High confidence Q1 FY27
    The Dombivli Hospital construction is progressing as per plan with an expected commissioning within a year in Q1 of FY '27.

    — Ankit Thakker

Construction Start

  • Pune Hospital construction start Construction Start · post monsoon · High confidence post monsoon
    The new Pune hospital is at the excavation stage after receiving all the environmental clearances. The construction is expected to begin post monsoon.

    — Ankit Thakker

Expansion Trigger

  • Indore Phase 2 expansion trigger Expansion Trigger · High confidence 60-65% occupancy
    See, like I just answered some time back, if you look at the occupancy for this quarter in Indore is 40%, 45%, right? Once this number reaches 60%, 65%, we will start thinking about expansion.

    — Ankit Thakker

What to watch in Q1 FY26

Indore occupancy ramp-up

next few quarters
Current 42.1% (Q4 FY25)
Target 60-65% (trigger for Phase 2 expansion)

Why it matters

Reaching target occupancy is crucial for triggering the next phase of expansion and improving asset utilization.

Once this number reaches 60%, 65%, we will start thinking about expansion.

Risks & concerns

  • Regulatory delays for Thane expansion

    medium

    Potential FSI increase and additional floor at Thane are contingent on environmental clearances and other statutory permissions, with no clear timeline.

    Management acknowledged

  • ARPOB growth moderation for mature hospitals

    medium

    ARPOB growth for Thane and Pune is expected to be inflation-linked, not the 10% seen in FY25, which could impact revenue growth if not offset by volume.

    Management acknowledged

  • Indore occupancy ramp-up period

    low

    Indore's Q4 occupancy was 42.1% after commissioning 78 new beds, indicating a ramp-up period is needed before further expansion (Phase 2).

    Management acknowledged

Q&A highlights

8 direct
ARPOB Growth Trajectory Direct
No, I don't expect 10% to continue. As I was saying that the projection for ARPOB growth should be inflation-linked. Thane and Pune, both are matured hospitals. So besides inflation, there is no other lever for ARPOB growth. Indore may be slightly higher than inflation because for maybe one more year, it has a second lever that is of case mix optimization that is more tertiary work.

Clarified that ARPOB growth for mature hospitals will normalize to inflation, while Indore might see higher growth due to case mix optimization for a limited period.

Asked by Amey from JM Financial

Thane Restructuring Rationale Direct
So now what is happening is that as you are seeing across the board, the length of stay for specific procedures and diseases is going down year-on-year with advancement of technology and medical science. So the supporting infrastructure is becoming more important and necessary. So we thought that we were in need of more operating rooms. We were falling short of our cath lab space.

Explained that the restructuring (e.g., removing economy wards) was driven by evolving clinical needs and technological advancements, requiring more advanced supporting infrastructure rather than just beds.

Asked by Amey from JM Financial

Pune Greenfield Capex and Land Terms Direct
So the new Pune hospital is supposed to be 500 beds in size. We think that the capex incurred for that project should be somewhere in the tune of INR500 crores excluding land. ... So the contours of the land deal are that currently, it is on a lease for 10 years without any escalation for the whole tenure. And after the third year is completed, we have a right to purchase the land.

Provided specific financial and structural details for the new Pune hospital project, including bed capacity, estimated capex, and the unique land lease-to-purchase arrangement.

Asked by Moksh Ranka from Aurum Capital

Indore Occupancy Decline in Q4 Direct
It's an expanded base. So we added 78 more beds. So in percentage terms, there is a dilution effect.

Addressed the reason for lower Q4 occupancy in Indore, attributing it to the recent commissioning of new beds, which temporarily dilutes the occupancy percentage.

Asked by Bino Pathiparampil from Elara Capital

Medulla Healthcare Scheme Restructuring Direct
So Medulla is a wholly owned subsidiary. It was activated during the COVID period where we were trying to create a separate entity to build and run our IT services. It was at that time, IT engineers, etc., were in a different mode. And they were not very keen to work with hospitals and some of them who were maintaining our unit at that time were wanting to commercialize healthcare software. ... So now this Medulla is not a functional entity. We are just carrying it on the books. So we thought that we should merge it and stop carrying one more entity.

Clarified the historical context and current rationale for merging Medulla Healthcare, indicating it was a non-functional IT services subsidiary that never materialized.

Asked by Prisha Rathi from NMK Securities

Inorganic Growth Strategy and Geographic Focus Direct
Yes. So there is no change in thought process on any front. A, to begin with, Western India remains the focus. B, full service flagship hub model continues to remain the focus. C, greenfield continues to remain a preferred choice. D, on the acquisition and brownfield front, like we have always said, if a good opportunity at a good value does present itself, we are not averse to it, but we will insist that the quality of asset and the value at which we are able to acquire it seems justifiable in our mind. ... currently, there is absolute clarity that we will not go beyond western part of India for now.

Reiterated the company's clear strategic focus on Western India for both greenfield and acquisition opportunities, emphasizing value and quality over mere expansion.

Asked by Abdulkader Puranwala from ICICI Securities

Thane Hospital Competition and Doctor Attrition Direct
Aashita, so yes, so far, not a single one of our senior doctors has moved out and stopped association with us. So we continue to report 0 attrition at the senior consultant level. Going forward also, I don't perceive that to be a major risk factor. ... I don't think that even if there is zero attrition from our side, the new hospitals will struggle in building teams. They will be able to build teams also. And with the population, I think on the demand side, there should not be challenge for any of the 3 hospitals.

Addressed concerns about increasing competition and doctor attrition in Thane, assuring that there has been zero attrition at the senior consultant level and that the market demand is sufficient.

Asked by Aashita Jain from Nuvama Institutional Equities

Thane Occupancy Ceiling Direct
So Thane hospital occupancies are 72% currently. Anything in mid-70% is, in our view, peak occupancy because we measure it at midnight. So there isn't too much scope to increase occupancy in Thane at current levels.

Provided clarity on the current occupancy levels at Thane, indicating that it is near its peak and there is limited scope for significant further increases.

Asked by Ashok Shah from Eklavya Invesco Family Office

3 min read 6 chapters

Detailed narrative

Strategic Expansion and Bed Capacity Targets

Jupiter Life Line Hospitals is actively pursuing its initial objective to establish 2,500 beds and expand its network from 3 to 6 hospitals in Western India, a target now 'within sight.' The company has commissioned 78 new beds at its Indore facility on January 1, 2025, and is progressing with greenfield projects in Dombivli and Pune, each planned for 500 beds. Dombivli is expected to be commissioned in Q1 FY27, while Pune's construction will commence post-monsoon, following receipt of all environmental clearances.

Robust Financial Performance in FY25

For the full financial year 2025, Jupiter Life Line Hospitals reported a total income of INR 1,261.5 crores, marking a 17.5% year-on-year growth. EBITDA for the year increased by 22.5% to INR 296.6 crores, achieving an EBITDA margin of 23.5%. The Average Revenue Per Occupied Bed (ARPOB) also saw a significant increase of 10.4% to INR 60,600, reflecting strong operational efficiency. Overall volume grew 11.2% to 9.8 lakhs in FY25, with an average occupancy of 65.3%.

Strategic Debt and Liquidity Management

The company has strategically raised additional debt to fund new projects and optimize growth. Its Indore subsidiary (JHPPL) secured INR 250 crores debt to repay an intercompany loan, making funds available for the listed entity. Additionally, the listed entity has a sanctioned loan of INR 350 crores for capex, with INR 75 crores already drawn and the remaining INR 275 crores available. This proactive approach has resulted in a strong cash position of approximately INR 600 crores, comprising INR 325 crores from new debt and INR 275 crores from existing reserves, with the cost of carrying the new loan expected to be less than 1%.

Brownfield Enhancements and Infrastructure Upgrades

Beyond new projects, Jupiter is investing in brownfield expansions and infrastructure upgrades. The Thane facility received approval for potential FSI increase, allowing for an additional floor, pending environmental clearances. Interim capex at Thane included reconfiguring a 22-bed economy ward to create two new operating theaters, a second MRI machine, a second cardiac cath lab, and expanding daycare/chemo suites from 14 to 22 beds, alongside a new OPD cluster and an overhaul of ageing engineering infrastructure like chillers and cooling towers.

Occupancy and ARPOB Outlook

The average occupancy for FY25 stood at 65.3%, an improvement of 150 basis points year-on-year, with Thane at 72.1%, Pune at 65.5%, and Indore at 54.9%. While ARPOB growth for mature hospitals like Thane and Pune is expected to align with inflation going forward, Indore may see slightly higher growth for another year due to case mix optimization. Q4 FY25 occupancy for Indore was 42.1%, a temporary dilution effect due to the recent commissioning of 78 new beds, and further expansion will be considered when occupancy reaches 60-65%.

Inorganic Growth and Geographic Focus

The company remains open to both greenfield and strategic acquisition opportunities, provided they meet criteria such as being in Western India, aligning with a full-service flagship hub model, and offering good value for quality assets. Management emphasized that there is 'absolute clarity' that they will not expand beyond Western India for now, prioritizing sensible acquisitions over a 'mindless race to add numbers and add speed.' The focus remains on full-service tertiary care, not just satellite OPD expansion.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls